Last reviewed · How we verify
NCT04359745
Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression
trial in Glioblastoma in 500 participants. Status unknown.
26 May 2024
Quick facts
| Lead sponsor | Guy's and St Thomas' NHS Foundation Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 21 March 2019 |
| Primary completion | 26 May 2024 |
| Estimated completion | 26 May 2025 |
| Sites | 15 locations across United Kingdom |
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
Sponsor
Guy's and St Thomas' NHS Foundation Trust
Who can join
Adults 18 to 80, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Glioblastoma is the most aggressive kind of brain cancer and leads on average to 20 years of life lost, more than any other cancer. MRI images of the brain are taken before the operation, and every few months after treatment, to see if the cancer regrows. It can be hard for doctors to tell if what they see in these images represent growing cancer or a sideeffect of treatment. The similarity of the appearance of the treatment side-effects to cancer is confusing and is known as "pseudoprogression" (as opposed to true cancer progression). If doctors mistake the appearance of treatment side-effects for growing cancer, they may think that the treatment is failing and change the patient's treatment too early or put them into a clinical trial. This means that patients may not be given the full treatment and the results from some clinical trials cannot be trusted. The aim of this study is to provide doctors with a computer program that will use MRI images of the brain that are routinely obtained throughout treatment, in order to help them more accurately identify when the cancer regrows.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Surgical data science - from concepts toward clinical translation.
Maier-Hein L, Eisenmann M, Sarikaya D, März K, et al · · 2022 · cited 158× · PMID 34879287 · DOI 10.1016/j.media.2021.102306 -
Artificial Intelligence in Neurosurgery: A State-of-the-Art Review from Past to Future.
Tangsrivimol JA, Schonfeld E, Zhang M, Veeravagu A, et al · · 2023 · cited 43× · PMID 37510174 · DOI 10.3390/diagnostics13142429
Verify or expand the search:
- PubMed search for NCT04359745
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Guy's and St Thomas' NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07534917 — Comparing the Effects of Newer Pacemakers and Their Effects on the Heart and Valve Function in the Short-term. · not yet recruiting
- NCT07454135 — Mechanisms of Atrial Pathoelectrophysiology in HCM · not yet recruiting
- NCT07419945 — Older Kidney Patient Optimisation Pretransplant · NA · not yet recruiting
- NCT07309835 — Improving Genetic Medicine for Ethnic Minority Groups · not yet recruiting
- NCT07203872 — Inflammation-resolution Therapy in MINST of Periodontal Intrabony Defect: a Pilot Randomised Controlled Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04359745 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guy's and St Thomas' NHS Foundation Trust
- Last refreshed: 21 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04359745.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing